The GLG Pharma STAT Blog

STAT3, Cancer and Genetics - GLG Pharma

Richard Gabriel — Wed, 26 Dec 2018 16:59:53 GMT

STAT or Signal Transducer and Activator of Transcription is a biological process in our normal cells that is as biologists like to say 'highly conserved'. At the Moffitt Cancer Center, the work of researchers funded by the NIH has led to the important discovery that certain compounds inhibit STAT at the phosphorylation, dimerization and also at the DNA binding site. Unlike the trans-membrane activated receptors which are 'up-stream' from STAT, STAT is a biological function that works ultimately on the DNA.

GLG Pharma STAT 3 Blog

Richard Gabriel — Wed, 26 Dec 2018 16:57:35 GMT

Welcome the first blog of our new website, GLG Pharma, LLC. We will try to cover a variety of topics related to STAT 3 inhibitors, cancer in general as well as other informative articles that we find on health, nutrition, exercise and cancer prevention and treatment.

GLG Pharma Announces Presentation at Upcoming AACR, the Annual Cancer Research Meeting 2015 April 18-22, 2015

Richard Gabriel — Mon, 23 Mar 2015 19:30:00 GMT

Jupiter, FL - March 23, 2015 – GLG Pharma, LLC, focused on developing drugs to prevent/treat cancer as well as other diseases mediated by dysfunctional STAT3 signaling, announced a NCI data presentation at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA. The study was sponsored by the PREVENT Cancer program of the National Cancer Institute of the NIH. The PREVENT Program is a National Cancer Institute-supported pipeline to bring new and novel cancer preventing interventions and biomarkers through preclinical development towards clinical trials.

GLG Pharma at Rare Disease Day Tallahassee Florida!

Richard Gabriel — Wed, 18 Feb 2015 21:47:20 GMT

FOR IMMEDIATE RELEASE

Why Work on Treatment or Cures for Rare Diseases?

Richard Gabriel — Wed, 28 Jan 2015 21:15:00 GMT

“Highlighting Chronic Lymphocytic Leukemia (CLL)”

WIIFM?

Richard Gabriel — Tue, 06 Jan 2015 19:54:00 GMT

(What's In It For Me?)

SEC Reviews Accredited Investor Requirements

Richard Gabriel — Fri, 02 Jan 2015 17:33:00 GMT

This is a short blog: The current debate at the SEC going on right now (December 17, 2014 and we have 60 days to comment on this as the general public) is about the definition of an accredited investor. There are two interesting presentations and anyone can down load by following the link we provide (click on Mary Jo White's picture).

Why Invest in Early Stage Drug Development for Rare Diseases?

Richard Gabriel — Mon, 08 Dec 2014 19:54:00 GMT

GLG Pharma Attending Faster Cures Partnering Nov. 16-18 NYC

Richard Gabriel — Sat, 15 Nov 2014 19:18:00 GMT

GLG Pharma Attending Partnering For Faster Cure

The Alpha-1 Antitrypsin Deficiency Walk!

Richard Gabriel — Mon, 10 Nov 2014 16:36:00 GMT